Sabbota et al., 2010 - Google Patents
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migrationSabbota et al., 2010
View PDF- Document ID
- 16513698527413295507
- Author
- Sabbota A
- Kim H
- Zhe X
- Fridman R
- Bonfil R
- Cher M
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
Membrane type 1 matrix metalloproteinase (MT1-MMP) plays an essential role in protease- mediated extracellular matrix (ECM) degradation, but it also functions as a sheddase releasing non-ECM substrates such as receptor activator of NF-κB ligand (RANKL), an …
- 102000014128 RANK Ligand 0 title abstract description 107
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabbota et al. | Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration | |
| Tang et al. | Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases | |
| Monami et al. | Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex | |
| Luo et al. | Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells | |
| Tang et al. | Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway | |
| Reddy et al. | Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells | |
| Paraiso et al. | Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy–mediated metastatic melanoma phenotype | |
| Kenny et al. | Targeting TACE-dependent EGFR ligand shedding in breast cancer | |
| Horak et al. | Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2 | |
| Mazzocca et al. | A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions | |
| Shield et al. | α2β1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis | |
| Scala et al. | Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma | |
| Baumgart et al. | ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non–small cell lung cancer | |
| Jamieson et al. | CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism | |
| Dubrovska et al. | Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma | |
| Azuma et al. | γ-Aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism | |
| Gong et al. | p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR | |
| Chen et al. | Complement factor H-related 5-hybrid proteins anchor properdin and activate complement at self-surfaces | |
| Vartanian et al. | VEGFR1 and PKCα signaling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner | |
| Unruh et al. | Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma | |
| Stellas et al. | Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis | |
| Margheri et al. | Endothelial progenitor cell–dependent angiogenesis requires localization of the full-length form of uPAR in caveolae | |
| Lindner et al. | α2-macroglobulin inhibits the malignant properties of astrocytoma cells by impeding β-catenin signaling | |
| All-Ericsson et al. | c-Kit–dependent growth of uveal melanoma cells: a potential therapeutic target? | |
| Zhang et al. | The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence |